ArticleBMC gastroenterology2010
Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor.
Article in BMC gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 195 citations in OpenAlex.
- Hepatic fibrosis extracellular matrix stiffness induces abnormal maturation of dendritic cell via AMPK inhibition-mediated cholesterol accumulation.Materials today. Bio · 2026Article
- Hepatoprotective effects of cinnamic acid against carbon tetrachloride-induced liver injury in a mouse model.Molecular biology reports · 2026Article
- SNX3 exacerbates hepatic fibrosis by amplifying TGF-Acta pharmaceutica Sinica. B · 2026Article
- An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.Journal of hepatology · 2026Article
- Article
- Resolvin D1 alleviates liver inflammation and fibrosis through SIRT1-mediated NF-κB and TGF-β1/Smads pathways.Journal of inflammation (London, England) · 2026Article
- Article
- TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches.Biotech (Basel (Switzerland)) · 2026Review
- Dynamic dual regulation of amphiregulin in liver pathophysiology: balancing regeneration and disease progression via the EGFR axis.Frontiers in medicine · 2026Review
- Artichoke Extract Ameliorates CCl4-Induced Hepatocellular Carcinoma in Albino Rats by Regulating the Phosphatidylinositol 3-kinase/serine-threonine Protein Kinase Pathway.Anti-cancer agents in medicinal chemistry · 2026Article
- Fibrosis in Immune-Mediated and Autoimmune Disorders.Journal of clinical medicine · 2025Review
- Long non-coding RNAMolecular therapy. Nucleic acids · 2025Review
- Navigating liver cancer with mouse models: a comprehensive overview of HCC experimental systems.Journal of liver cancer · 2025Article
- Amniotic Fluid Reduces Liver Fibrosis By Attenuating Hepatic Stellate Cell Activation.bioRxiv : the preprint server for biology · 2025Article
- Amphiregulin in Fibrotic Diseases and Cancer.International journal of molecular sciences · 2025Review
- Amniotic fluid reduces liver fibrosis by attenuating hepatic stellate cell activation.Stem cells translational medicine · 2025Article
- Misery Loves Company: Interplay Between Chronic Liver Disease and Cardiac Remodeling.JACC. Basic to translational science · 2025Article
- Can disulfiram modulate liver injury in CCl4-induced fibrosis in rats?Gastroenterology and hepatology from bed to bench · 2025Article
- Exploring the mechanism of action of Jinqiancao granules against liver cirrhosis based on the liver-gut axis.Frontiers in pharmacology · 2025Article
- Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models.Theranostics · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn the setting of chronic liver injury in humans, epidermal growth factor (EGF) and EGF receptor (EGFR) are up-regulated and have been proposed to have vital roles in both liver regeneration and development of hepatocellular carcinoma (HCC). Chronic liver injury also leads to hepatic stellate cell (HSC) differentiation and a novel subpopulation of HSCs which express CD133 and exhibit properties of progenitor cells has been described in rats. The carbon tetrachloride (CCl4)-induced mouse model has been historically relied upon to study liver injury and regeneration. We exposed mice to CCl4 to assess whether EGF and CD133+ HSCs are up-regulated in chronically injured liver.
methodsCCl4 in olive oil was administered to strain A/J mice three times per week by oral gavage.
resultsMultiple well-differentiated HCCs were found in all livers after 15 weeks of CCl4 treatment. Notably, HCCs developed within the setting of fibrosis and not cirrhosis. CD133 was dramatically up-regulated after CCl4 treatment, and increased expression of desmin and glial fibrillary acidic protein, representative markers of HSCs, was also observed. EGF expression significantly decreased, contrary to observations in humans, whereas the expression of amphiregulin, another EGFR ligand, was significantly increased.
conclusionsSpecies-specific differences exist with respect to the histopathological and molecular pathogenesis of chronic liver disease. CCl4-induced chronic liver injury in A/J mice has important differences compared to human cirrhosis leading to HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.